Dose-response association of CD8 tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer

EL Goode; MS Block; KR Kalli; RA Vierkant; W Chen; ZC Fogarty; A Gentry-Maharaj; A Tołoczko; A Hein; AL Bouligny; A Jensen; A Osorio; AD Hartkopf; A Ryan; A Chudecka-Głaz; AM Magliocco; A Hartmann; AY Jung; B Gao; BY Hernandez; BL Fridley; BM McCauley; CJ Kennedy; C Wang; C Karpinskyj; CB de Sousa; DG Tiezzi; DL Wachter; E Herpel; FA Taran; F Modugno; G Nelson; J Lubiński; J Menkiszak; J Alsop; J Lester; J Garcia-Donas; J Nation; J Hung; J Palacios; JH Rothstein; JL Kelley; JM de Andrade; L Robles-Diaz; MP Intermaggio; M Widschwendter; MW Beckmann; M Ruebner; M Jimenez-Linan; N Singh; O Oszurek; PR Harnett; PF Rambau; P Sinn; P Wagner; P Ghatage; R Sharma; RP Edwards; RB Ness; S Orsulic; SY Brucker; SE Johnatty; TA Longacre; U Eilber; V McGuire; W Sieh; Y Natanzon; Z Li; AS Whittemore; A deFazio; A Staebler; BY Karlan; B Gilks; DD Bowtell; E Hogdall; FJ Candido dos Reis; H Steed; IG Campbell; J Gronwald; J Benitez; JM Koziak; J Chang-Claude; KB Moysich; LE Kelemen; LS Cook; MT Goodman; MJ Garcia; PA Fasching; S Kommoss; S Deen; SK Kjaer; U Menon; JD Brenton; PDP Pharoah; G Chenevix-Trench; DG Huntsman; SJ Winham; M Kobel; SJ Ramus

Journal article

Dose-response association of CD8 tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer

EL Goode, MS Block, KR Kalli, RA Vierkant, W Chen, ZC Fogarty, A Gentry-Maharaj, A Tołoczko, A Hein, AL Bouligny, A Jensen, A Osorio, AD Hartkopf, A Ryan, A Chudecka-Głaz, AM Magliocco, A Hartmann, AY Jung, B Gao, BY Hernandez Show all

JAMA Oncology | Published : 2017

DOI: 10.1001/jamaoncol.2017.3290

Abstract

IMPORTANCE Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors. OBJECTIVE To define the prognostic role of CD8+ TILs in epithelial ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years. EXPOSURES Following immunohistochemical analysis, CD8+ TILs were ide..

View full abstract

University of Melbourne Researchers

David Bowtell Author

Ian Campbell Author

Related Projects (5)

Australian Biospecimen Network-Oncology

Availability of ethically consented, clinically annotated human cancer tissue is a key determinant of the international competitiveness of A..

AUSTRALASIAN BIOSPECIMEN NETWORK-ONCOLOGY

Molecular Epidemiology of Ovarian Research Institute

PUBLIC ABSTRACT A major obstacle to preventive strategies for ovarian cancer is the lack of recognized modifiable risk factors. Age, a pos..

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

Grants

Awarded by Cancer Council Victoria

Funding Acknowledgements

Funding was provided by Canadian Institutes for Health Research (MOP 86727); Brazilian National Council for Scientific and Technological Development, grant No. 478416/2009-1; Calgary Laboratory Services Internal Research Competition RS10-533; German Federal Ministry of Education and Research of Germany (01 GB 9401); German Cancer Research Center (DIKFZ); US National Cancer Institute K07-CA80668, P50-CA159981, R01CA095023; National Institutes of Health/National Center for Research Resources/General Clinical Research Center grant M01-RR000056; US Army Medical Research and Materiel Command DAMD17-02-1-0669; NIH (R01-CA122443, P50-CA136393, P30-CA15083, U01-CA71966, U01-CA69417, R01-CA16056, K07-CA143047); Cancer Research UK (C490/A10119, C490/A10123, 6490/A16561); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge and at University College Hospital, "Women's Health Theme"; NIH SIB 685; the Eve Appeal; the Oak Foundation; and Deutsche Forschungsgemeinschaft. The Australian Ovarian Cancer Study Group was supported by the US Army Medical Research and Materiel Command under DAMD17-01-1-0729; The Cancer Council Victoria; Queensland Cancer Fund; The Cancer Council, New South Wales,; the Tom Baker Cancer Centre Translational Laboratories; The Cancer Council, South Australia; The Cancer Foundation of Western Australia; The Cancer Council Tasmania; and the National Health and Medical Research Council of Australia (NHMRC; 10400413, 10400281). The AOCS gratefully acknowledges additional support from the Peter MacCallum Cancer Foundation and Ovarian Cancer Australia (OCA). The Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group, was funded by the National Health and Medical Research Council Enabling grants ID 310670 and ID 628903 and the Cancer Institute NSW grants 12/RIG/1-17 and 15/RIG/116. Funding for MALOVA was provided by research grant R01-CA61107 from the National Cancer Institute, Bethesda, Maryland; research grant 9422252 from the Danish Cancer Society, Copenhagen, Denmark; and the Mermaid I project. Drs DeFazio and Harnett are funded by Cancer Institute NSWgrant 15/TRC/1-01. Dr Karlan is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS), grant UL1TR000124.